Biosolution Co.,Ltd.
Financials
Valuation Metrics
Biosolution Co.,Ltd.'s Market Cap is ₩1667B. At end of 2025 it was ₩2051B. Ranked #961 of 2,421 in KR market (top 40%), #470 of 1,640 on KOSDAQ (top 29%), #109 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 47%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 166.69B KRW | KR#961/2,421 Sec#109/231 |
| Revenue | 17.39B KRW | KR#2,180/2,421 Sec#160/231 |
| Net Income | 869.0M KRW | KR#1,489/2,421 Sec#102/231 |
| Total Assets | 66.27B KRW | KR#2,047/2,421 Sec#174/231 |
| Net Assets | 41.31B KRW | KR#2,029/2,421 Sec#177/231 |
| Employees | 88 | KR#1,741/2,421 Sec#138/231 |
| Value | ||
| P/E | 191.83x | KR#1,523/2,421 Sec#105/231 |
| P/B | 4.04x | KR#2,194/2,421 Sec#179/231 |
| P/S | 9.58x | KR#2,273/2,421 Sec#163/231 |
| FCF Yield | -0.90% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 2.10% | KR#1,398/2,421 Sec#96/231 |
| ROA | 1.31% | KR#1,352/2,421 Sec#97/231 |
| Op. Margin | -19.35% | KR#2,111/2,421 Sec#143/231 |
| Revenue Growth | 30.88% | KR#379/2,421 Sec#37/231 |
| Financial Health | ||
| Debt Ratio | 60.42% | KR#1,098/2,421 Sec#128/231 |
| Total Debt | 18.68B KRW | KR#1,401/2,421 Sec#112/231 |
| FCF | -1.50B KRW | KR#1,309/2,421 Sec#102/231 |
| Cash | 9.28B KRW | KR#1,737/2,421 Sec#150/231 |
| Current Ratio | 0.84x | KR#1,907/2,421 Sec#186/231 |
| Performance | ||
| 1Y Return | -26.68% | KR#1,459/2,421 Sec#110/231 |
| 1M Return | -3.45% | KR#1,639/2,421 Sec#130/231 |
| From 52W High | -52.19% | KR#1,497/2,421 Sec#115/231 |
| 1Y MDD | -57.45% | KR#1,333/2,421 Sec#111/231 |
| Trading | ||
| Volume | 53,002 shares | KR#1,100/2,421 Sec#109/231 |
| Trading Value | 340.2M KRW | KR#1,082/2,421 Sec#110/231 |
| Foreign Own. | 2.05% | KR#1,606/2,421 Sec#153/231 |
| Per Share | ||
| EPS | 34 KRW | KR#1,520/2,421 Sec#104/231 |
| BPS | 1,594 KRW | KR#2,170/2,421 Sec#185/231 |
Company Info
Established in 2000 as a cell therapy developer, the company changed its name in 2016, listed on KOSDAQ in 2018, and established local subsidiaries in China and Australia during the current period. It operates businesses in cell therapies, human stem cell-derived materials, peptide cosmetic ingredients, human tissue models, and alternative testing services. Following the commercialization of autologous cell therapies, the company is developing allogeneic cell therapies to expand commercialization and versatility. It is also expanding cosmetic ingredients through market expansion via human tissue model certification and joint research. BIOSOLUTIONS is headquartered in Nowon-gu, Seoul.